MM1.s CDX Model

The MM1.s cell line is derived from human multiple myeloma, a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow. Multiple myeloma often results in bone lesions, anemia, and renal dysfunction. The MM1.s cell line provides a critical framework for understanding the underlying biology, progression, and therapeutic interventions for this disease. Exhibiting key molecular features and genetic mutations commonly observed in multiple myeloma patients, MM1.s stands as a representative model for preclinical studies. Its behavior, both in vitro and in vivo, illuminates the proliferative dynamics of myeloma cells, their interactions within the bone marrow microenvironment, and their responses to various therapeutic agents. Researchers extensively utilize MM1.s to delve into the disease’s pathogenesis, to investigate the efficacy of novel therapeutic compounds, and to elucidate mechanisms of drug resistance in multiple myeloma.

Model Details

Cancer Location: Intravenous
Cancer Type: Multiple Myeloma
Model Name: MM1.s
Mouse Strain: Nu/Nu, NOD SCID
Treatment Data Available: Chemotherapy (Lenalidomide, Dexamethasone, Pomalidomide, Daratumumab, Elotuzumab)

BT-474 Growth curves

MM1.s CDX Model

Growth of subcutaneous MM1.S in Nu/Nu mice (n=10)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.